[1] Cruz-Jentoft AJ, Sayer AA. Sarcopenia[J]. Lancet, 2019, 393(10191): 2636-2646.
[2] Fonseca GWPD, Santos MRD, Souza FR, et al. Sympatho-vagal imbalance is associated with sarcopenia in male patients with heart failure[J]. Arq Bras Cardiol, 2019, 112(6): 739-746.
[3] Attaway A, Bellar A, Dieye F, et al. Clinical impact of compound sarcopenia in hospitalized older adult patients with heart failure[J]. J Am Geriatr Soc, 2021, 69(7): 1815-1825.
[4] Jaiswal N, Gavin M, Loro E, et al. AKT controls protein synthesis and oxidative metabolism via combined mTORC1 and FOXO1 signalling to govern muscle physiology[J]. J Cachexia Sarcopenia Muscle, 2022, 13(1): 495-514.
[5] Yoon MS. mTOR as a key regulator in maintaining skeletal muscle mass[J]. Front Physiol, 2017, 8: 788.
[6] Willis MS, Parry TL, Brown DI, et al. Doxorubicin exposure causes subacute cardiac atrophy dependent on the striated muscle-specific Ubiquitin Ligase MuRF1[J]. Circ Heart Fail, 2019, 12(3): 1-12.
[7] Adams V, Linke A, Winzer E. Skeletal muscle alterations in HFrEF vs. HFpEF[J]. Curr Heart Fail Rep, 2017, 14(6): 489-497.
[8] Rom O, Reznick AZ. The role of E3 ubiquitin-ligases MuRF-1 and MAFbx in loss of skeletal muscle mass[J]. Free Radic Biol Med, 2016, 98: 218-230.
[9] Cho J, Choi Y, Sajgalik P, et al.Exercise as a therapeutic strategy for sarcopenia in heart failure: insights into underlying mechanisms[J]. Cells, 2020, 9(10): 2284.
[10] Sakuma K, Aoi W, Yamaguchi A. Current understanding of sarcopenia: possible candidates modulating muscle mass[J]. Pflugers Arch, 2015, 467(2): 213-229.
[11] Liao ZY, Chen JL, Xiao MH, et al.The effect of exercise, resveratrol or their combination on Sarcopenia in aged rats via regulation of AMPK/Sirt1 pathway[J]. Exp Gerontol, 2017, 98(11): 177-183.
[12] Filippatos GS, Kanatselos C, Manolatos DD, et al. Studies on apoptosis and fibrosis in skeletal musculature: a comparison of heart failure patients with and without cardiac cachexia[J]. Int J Cardiol, 2003, 90(1): 107-113.
[13] Guo SH, Gong MQ, Tse G, et al. The Value of IGF-1 and IGFBP-1 in patients with heart failure with reduced, mid-range, and preserved ejection fraction[J]. Front Cardiovasc Med, 2021, 8772105.
[14] Ascenzi F, Barberi L, Dobrowolny G, et al. Effects of IGF-1 isoforms on muscle growth and sarcopenia[J]. Aging cell, 2019, 18(3): e12954.
[15] Yoshihihisa A, Suzuki S, Sato Y, et al. Relation of testosterone levels to mortality in men with heart failure[J]. Am J Cardiol, 2018, 121(11): 1321-1327.
[16] Gharahdaghi N, Rudrappa S, Brook MS, et al. Testosterone therapy induces molecular programming augmenting physiological adaptations to resistance exercise in older men[J]. J Cachexia Sarcopenia Muscle, 2019, 10(6): 1276-1294.
[17] Colla AL, Pronsato L, Milanesi L, et al. 17β-Estradiol and testosterone in sarcopenia: Role of satellite cells[J]. Ageing Res Rev, 2015, 24(Pt B): 166-177.
[18] Pronsato L, Milanesi L, Vasconsuelo A. Testosterone induces up-regulation of mitochondrial gene expression in murine C2C12 skeletal muscle cells accompanied by an increase of nuclear respiratory factor-1 and its downstream effectors[J]. Mol Cell Endocrinol, 2020, 500: 110631.
[19] Pronsato L, Milanesi L, Vasconsuelo A, et al.Testosterone modulates FoxO3a and p53-related genes to protect C2C12 skeletal muscle cells against apoptosis[J]. Steroids, 2017, 124(5): 35-45.
[20] Müller TD, Nogueiras R, Andermann ML, et al. Ghrelin [J]. Mol Metab, 2015, 4(6): 437-460.
[21] Yuan MJ, Li W, Zhong P.Research progress of ghrelin on cardiovascular disease[J]. Biosci Rep, 2021, 41(1): 1-6.
[22] Barazzoni R, Cappellari GG, Palus S, et al. Acylated ghrelin treatment normalizes skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rat chronic heart failure[J]. J Cachexia Sarcopenia Muscle, 2017, 8(6): 991-998.
[23] Meloux A, Rochette L, Maza M, et al. Growth differentiation Factor-8 (GDF8)/Myostatin is a predictor of Troponin I peak and a marker of clinical severity after acute myocardial infarction[J]. J Clin Med, 2019, 9(1): 116-126.
[24] Braun TP, Marks DL. The regulation of muscle mass by endogenous glucocorticoids[J]. Front Physiol, 2015, 6(3): 1-12.
[25] Sriram S, Subramanian S, Sathiakumar D, et al. Modulation of reactive oxygen species in skeletal muscle by myostatin is mediated through NF‐κB[J]. Aging Cell, 2011, 10(6): 931-948.
[26] Katano S, Yano T, Shimizu M, et al.Does renin-angiotensin system inhibition have impacts on muscle mass and bone mineral density in heart failure patients[J]. ESC heart failure, 2021, 8(4): 2617-2624.
[27] Sullivan RD, Mehta RM, Tripathi R, et al. Normalizing plasma renin activity in experimental dilated cardiomyopathy: effects on edema, cachexia, and survival[J]. Int J Mol Sci, 2019, 20(16): 3386.
[28] Tuttle CSL, Thang LAN, Maier AB. Markers of inflammation and their association with muscle strength and mass: A systematic review and meta-analysis[J]. Ageing Res Rev, 2020, 64(12): 1568-1637.
[29] Rong YD, Bian AL, Hu HY, et al. Study on relationship between elderly sarcopenia and inflammatory cytokine IL-6, anti-inflammatory cytokine IL-10[J]. BMC Geriatr, 2018, 18(1): 308.
[30] Koshikawa M, Harada M, Noyama S, et al. Association between inflammation and skeletal muscle proteolysis, skeletal mass and strength in elderly heart failure patients and their prognostic implications [J]. BMC Cardiovasc Disord, 2020, 20(1): 228-237
[31] Wang Y, Welc SS, Wehling-henbricks M, et al. Myeloid cell-derived tumor necrosis factor-alpha promotes sarcopenia and regulates muscle cell fusion with aging muscle fibers [J]. Aging Cell, 2018, 17(6): e12828.
[32] Yalcin A, Silay K, Balik AR, et al.The relationship between plasma interleukin-15 levels and sarcopenia in outpatient older people[J]. Aging Clin Exp Res, 2018, 30(7): 783-790.
[33] Linthout SV, Tschpe C.Inflammation - cause or consequence of heart failure or both?[J]. Curr Heart Fail Rep, 2017, 14(4): 251-265.
[34] Kiyuna LA, Albuquerque R, Chen CH, et al.Targeting mitochondrial dysfunction and oxidative stress in heart failure: Challenges and opportunities[J]. Free Radic Biol Med, 2018, 129(12): 155-168.
[35] Shirakawa R, Yokota T, Nakajima T, et al.Mitochondrial reactive oxygen species generation in blood cells is associated with disease severity and exercise intolerance in heart failure patients [J]. Sci Rep, 2019, 9(1): 14709.
[36] Hideo N, Shingo T, Satoshi M, et al.Inhibition of xanthine oxidase in the acute phase of myocardial infarction prevents skeletal muscle abnormalities and exercise intolerance[J]. Cardiovasc Res, 2021, 117(3): 805-819.
[37] Santos VR, Correa BD, Pereira CGDS, et al.Physical activity decreases the risk of sarcopenia and sarcopenic obesity in older adults with the incidence of clinical factors: 24-month prospective study[J]. Exp Aging Res, 2020, 46(2): 166-177.
[38] Marzetti E, Calvani R, Tosato M, et al. Physical activity and exercise as countermeasures to physical frailty and sarcopenia[J]. Aging Clin Exp Res, 2017, 29(1): 35-42.
[39] Shou J, Chen PJ, Xiao WH. Mechanism of increased risk of insulin resistance in aging skeletal muscle[J]. Diabetol Metab Syndr, 2020, 12(14): 1-10.
[40] Wamil M, Coleman RL, Adler AI, et al. Increased risk of incident heart failure and death is associated with insulin resistance in people with newly diagnosed Type 2 diabetes: UKPDS 89 [J]. Diabetes Care, 2021, 44(8): 1877-1884.
[41] Alway SE, Mohamed JS, Myers MJ. Mitochondria initiate and regulate sarcopenia[J]. Exerc Sport Sci Rev, 2017, 45(2):58-69.
[42] Consitt LA, Dudley C, Saxena G. Impact of endurance and resistance training on skeletal muscle glucose metabolism in older adults[J]. Nutrients, 2019, 11(11):2636-2653.
[43] Ferri E, Marzetti E, Calvani R, et al.Role of age-related mitochondrial dysfunction in sarcopenia [J]. Int J Mol Sci, 2020, 21(15): 5236-5248.
[44] Garnham JO, Roberts LD, Caspi T, et al. Divergent skeletal muscle mitochondrial phenotype between male and female patients with chronic heart failure[J]. J Cachexia Sarcopenia Muscle, 2020, 11(1): 79-88.
[45] Liang JJ, Zhang H, Zeng ZZ, et al. Lifelong aerobic exercise alleviates sarcopenia by activating autophagy and inhibiting protein degradation via the AMPK/PGC-1α signaling pathway[J]. Metabolites, 2021, 11(5): 323-335.
